25th week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220193074 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS - The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor. | 2022-06-23 |
20220193075 | THERAPEUTIC DRUG FOR DYSKINESIA - The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered. | 2022-06-23 |
20220193076 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB - The invention provides tucatinib and its use in methods of treating cancer, such as breast cancer. The invention also provides compositions and kits comprising tucatinib for use in treating cancer, such as breast cancer. | 2022-06-23 |
20220193077 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A EGFR-INHIBITOR FOR TREATING SOLID TUMORS - Provided herein are combination therapies comprising a KRas | 2022-06-23 |
20220193078 | METHODS FOR TREATING OCULAR SURFACE PAIN - The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile. | 2022-06-23 |
20220193079 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof. | 2022-06-23 |
20220193080 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR - The present invention relates to the discovery of small molecule compounds that act as GLP-1R agonists and/or as positive allosteric modulators (PAMs) of GLP-1R. Such compounds are useful to treat, ameliorate, and/or prevent insulin resistance and/or diabetes in a mammal. | 2022-06-23 |
20220193081 | LIQUID SILDENAFIL CITRATE COMPOSITIONS - The invention is directed to liquid pharmaceutical compositions comprising at least 15mg/ml of sildenafil citrate, their use in treating erectile dysfunction and their methods of manufacture. | 2022-06-23 |
20220193082 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY - Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome. | 2022-06-23 |
20220193083 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS - Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor. | 2022-06-23 |
20220193084 | INHIBITORS OF EZH2 AND METHODS OF USE THEREOF - The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. | 2022-06-23 |
20220193085 | METHODS OF THROMBOPROPHYLAXIS - Methods of thromboprophylaxis using rivaroxaban is provided for children with congenital heart disease post-Fontan procedure. | 2022-06-23 |
20220193086 | COMBINATION THERAPY - Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient. | 2022-06-23 |
20220193087 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS - The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout. | 2022-06-23 |
20220193089 | COMBINATIONS INCLUDING ABX196 FOR THE TREATMENT OF CANCER - An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer. | 2022-06-23 |
20220193090 | METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE - Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose. | 2022-06-23 |
20220193091 | COMBINED ADMINISTRATION OF DIAZEPAM AND DICLOFENAC FOR THE TREATMENT OF PAIN - A pharmaceutical composition consisting of a combined preparation of diazepam and diclofenac sodium for use as a combined preparation, in the form of tablets, capsules, injection, infusion, drinking ampoules or drops, for the combined administration of diazepam and diclofenac sodium for the short-term specific treatment of pain based on the indication of disc herniation, lower back pain, lumboischialgia, dorsalgia, cervicalgia, cervical neuralgia, sciatica, chronic joint pain, migraine, headache, joint pain, myocardial infarction, post-operative pain, broken bones, burns, tumour pain or tumour-related pain, rheumatism, toothache, pain caused by drug withdrawal, pain that cannot be localised or pain without a known cause, pain caused by fasciae and conjunctive tissue, phantom pain following amputations, combinations of the aforementioned pains and other pains. | 2022-06-23 |
20220193092 | PROGESTOGEN FOR USE IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - Disclosed is a method and a composition for inhibiting cytokine storm in a subject in need thereof, in particular cytokine release from PBMCs induced by anti-CD28 antibody and/or anti-CD3 antibody, comprising administering progestogen to the subject. The results show that hydroxyprogesterone caproate could inhibit various cytokines release from PBMC induced by anti-CD28 antibody and/or anti-CD3 antibody in a concentration-dependent manner, and could be a potential drug for the treatment of cytokine storm. | 2022-06-23 |
20220193093 | HIGH CONCENTRATION FORMULATION - The present disclosure provides high concentration formulations of cortexolone-17α-propionate suitable for treating alopecia. | 2022-06-23 |
20220193094 | AQUEOUS ORAL PHARMACEUTICAL SUSPENSION COMPOSITIONS - Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use. | 2022-06-23 |
20220193095 | PHARMACEUTICAL COMPOSITIONS - Provided are pharmaceutical compositions which comprise a mixture of a lipophilic active pharmaceutical ingredient, at least one long chain fatty acid or at least one fatty acid glyceride, a surfactant, and optionally an antioxidant. Also described are methods for preparing and using such pharmaceutical compositions. The active pharmaceutical ingredient in such a combination has improved bioavailability compared to the active pharmaceutical ingredient alone. | 2022-06-23 |
20220193096 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY - Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NC | 2022-06-23 |
20220193097 | USE OF 1-DI-ISOPROPYL-PHOSPHINOYL-ALKANE COMPOUNDS FOR TREATMENT OF OCULAR DISCOMFORT - The present invention pertains to methods of using certain 1-di-isopropyl-phosphinoylalkanes as described herein (DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) for the treatment of ocular discomfort that is caused by eye strain; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; heat discomfort; extended wear of contact lenses; excessive exposure to the sun; asthenopia; conjunctivitis; or a dry eye syndrome. The present invention also pertains to pharmaceutical compositions comprising such compounds, and media contain those pharmaceutical compositions. | 2022-06-23 |
20220193098 | COMPOSITION FOR USE IN PREVENTION OR REDUCTION OF OXIDATIVE STRESS AND NEURODEGENERATIVE DISEASES - Disclosed is compositions including L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine for use in prevention of oxidative stress of cells. The compositions are also suitable for use in preventing and/or correcting neurodegenerative damages in a subject suffering from one Parkinson disease, Huntington disease and Alzheimer disease. Also disclosed is a colostrum-based dietary supplement enriched with L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine. | 2022-06-23 |
20220193099 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN - The disclosure provides for methods of treating pain and neuroinflammatory pain conditions with certain oligosaccharides. | 2022-06-23 |
20220193100 | COMPOSITION CONTAINING GLUCORAPHANIN AND USE THEREOF - The present disclosure relates to a composition comprising glucoraphanin and its therapeutic use. | 2022-06-23 |
20220193101 | Methods for treating and Pharmaceutical compositions - The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil. | 2022-06-23 |
20220193102 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) - Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and (b) an SGLT-2 inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or a GLP-1 receptor agonist, or a pharmaceutically acceptable salt or solvate thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I) and an SGLT-2 inhibitor or a GLP-1 receptor agonist. | 2022-06-23 |
20220193103 | NANO-PUERARIN REGULATES TUMOR MICROENVIRONMENT AND FACILITATES CHEMO- AND IMMUNOTHERAPY IN MURINE TRIPLE NEGATIVE BREAST CANCER MODEL - Disclosed are nanoemulsions comprising puerarin and methods of their use in treating cancer, including breast cancer and melanoma. The presently disclosed puerarin-containing nanoemulsions regulate the tumor microenvironment and importantly de-activate tumor associated fibroblasts (TAFs) rather than killing them. The presently disclosed methods can be used in combination with chemotherapy, e.g., polymer formulations of paclitaxel, or PD-L1 blockade therapy to treat cancer. | 2022-06-23 |
20220193104 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF - A compound for regulating body weight imbalance, a composition thereof and an application thereof. The inventor unexpectedly discovered that diosmin hydrogen sulfate derivatives have the effects of regulating body weight imbalance, and are expected to be developed as safe and effective weight imbalance regulators or used as synergists to improve the regulatory effects of existing weight imbalance regulators. | 2022-06-23 |
20220193105 | PH RESPONSIVE DRUG CONJUGATED NANOCARRIERS - The presently disclosed invention relates to products and methods of treating cancer in a patient comprising administering to the patient a pharmaceutically therapeutic dose of a chemotherapeutic, or any pharmaceutically acceptable salt, solvate, or prodrug thereof, conjugated to a nanocarrier. According to a further embodiment, the chemotherapeutic has a primary (1 | 2022-06-23 |
20220193106 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS - Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed. | 2022-06-23 |
20220193107 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER - Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters. | 2022-06-23 |
20220193108 | Immunotherapeutic Nanoparticles And Methods Relating Thereto - Compositions containing lipid nanoparticles and nucleic acid therapeutic agents are disclosed. For example, calcium phosphate nanoparticles having a lipid coating are provided, wherein the calcium phosphate nanoparticles include a cyclic dinucleotide and the lipid coating includes phosphatidylserine. The compositions can be formulated for administration to the lungs of a subject via inhalation, or for administration via injection. Methods for the treatment of lung cancer and other cancers are also described. Targeted delivery of therapeutic agents such as cyclic dinucleotides to antigen presenting immune cells via the disclosed methods can elicit beneficial antitumor immunity. | 2022-06-23 |
20220193109 | COMPOSITIONS AND METHODS FOR TREATING RAS-MUTANT CANCERS - The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer). | 2022-06-23 |
20220193110 | NXTAR-DERIVED OLIGONUCLEOTIDES AND USES THEREOF - Among the various aspects of the present disclosure is the provision of a NXTAR-derived oligonucleotides and uses thereof. An aspect of the present disclosure provides for a method of (i) suppressing androgen receptor (AR) expression, (ii) suppressing androgen receptor splice variants (including AR-V7) expression, (iii) treating cancer (e.g., prostate, breast, testis, ovarian, endometrial and skin) (iv) treating skin related diseases, such as androgenetic alopecia and acne vulgaris in a subject comprising administering to the subject a NXTAR-derived oligonucleotide (oligo) (NXTAR is a lncRNA also known as LOC105373241). | 2022-06-23 |
20220193111 | Method of Treatment - Described herein are methods for the regulation of angiogenesis and endothelial to mesenchymal transition, the methods involving administration of modulators of miRNA-148b levels. Also described are the use of modulators of miRNA-148b levels in medical treatments such as the treatment of wounds, in particular soft tissue wounds. | 2022-06-23 |
20220193112 | HETERO-STRUCTURED RIBONUCLEIC ACID AND USE THEREOF - A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided. | 2022-06-23 |
20220193113 | NOVEL THERAPEUTIC AGENT FOR GASTROINTESTINAL CANCER AND METHOD FOR SCREENING FOR THE SAME - The present invention provides a therapeutic agent for gastrointestinal cancer, comprising an Arid5A inhibitor as an active ingredient; and a method for screening for a candidate substance useful for treating gastrointestinal cancer, comprising the steps of: (1) examining whether a test substance affects Arid5A expression, and (2) identifying the test substance as screen positive when the test substance is capable of reducing Arid5A expression based on comparison of cases with and without the test substance. | 2022-06-23 |
20220193114 | NEUROGENESIS - Methods and compositions for increasing neurogenesis and for preventing or treating diseases, disorders or conditions associated with neurodegeneration, are provided herein. | 2022-06-23 |
20220193115 | SELF-ASSEMBLED NANO-FIBERS AS HEMOSTATIC AGENT - A composition has a polyanionic component comprising casein or derivatives thereof, and a polycationic component, which includes chitosan or derivatives thereof. The composition is in the form of nanofibers having a diameter in a range of 20-200 nm. Also disclosed is a process for preparing the composition and a hemostatic article with the composition. A method for inhibiting loss of blood from a hemorrhaging site involves use of the composition and the hemostatic article. | 2022-06-23 |
20220193116 | CROSS-LINKED HYALURONIC ACIDS AND COMBINATIONS WITH PRP/BMC - The invention provides a new method of synthesizing cross-linked hyaluronic acids, compositions thereof, tubes and syringes containing such compositions alone or in combination with PRP/BMC, new devices for PRP/BMC preparation, and uses thereof in cell culture, skincare and joint preservation. The invention provides a method for the production of a crosslinked gel (preferably of desired molecular weight and/or concentration) from at least one first polymer (preferably hyaluronic acid), comprising the steps of: homogenizing said first polymer, hydrating said first polymer in a basic solution, crosslinking said basic solution by adding at the least one crosslinking agent at a higher temperature than room temperature, neutralizing said basic solution in an acidic solution, homogenizing said solution, mixing said solution with a supplemental quantity of a second polymer (preferably a second polymer of substantially the same molecular weight and/or concentration as said first polymer), and purifying said solution. | 2022-06-23 |
20220193117 | Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer - This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid. | 2022-06-23 |
20220193118 | METHOD FOR SUPPRESSING INTERVERTEBRAL DISC PAIN - Provided is a composition for suppressing pain which contains a monovalent metal salt of alginic acid, the composition being applied to a nucleus pulposus cavity part to suppress pain at a surgical site and/or a surrounding site thereof which occurs after surgery. Accordingly, a composition is provided, which suppresses pain and/or inflammation at a surgical site and/or a surrounding site thereof which occurs after surgery performed on an intervertebral disc as typified by intervertebral discectomy. | 2022-06-23 |
20220193119 | ANTISEPTIC SKIN PREP COMPOSITION - The disclosed antiseptic composition has improved stability, flow control and tinting ability is provided. The antiseptic composition comprises a cationic antiseptic, an anionic tinting agent, a polymer that serves as a stabilizer and preferably a viscosity builder, an alcohol-based solvent and optionally a plasticizer and viscosity builder. | 2022-06-23 |
20220193120 | MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR MAINTAINING LUNG FUNCTION IN HUMAN LUNG CANCER AND/OR IMPROVING REDUCTION IN LUNG FUNCTION ATTRIBUTED TO HUMAN LUNG CANCER - The present invention provides a composition for maintaining a lung function in a human lung cancer and/or improving a reduction in lung function attributed to the human lung cancer. More specifically, the present invention provides a composition for maintaining a lung function in a human lung cancer and/or improving a reduction in lung function attributed to the human lung cancer in a subject, comprising molecular hydrogen as an active ingredient. | 2022-06-23 |
20220193121 | COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOF - Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate. | 2022-06-23 |
20220193122 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS - The disclosure provides methods and compositions for treating heart conditions. In particular, the disclosure provides compositions comprising lithium, or a salt thereof, either alone or in combination with at least one additional anti-arrhythmia agent, and methods for treating heart conditions using such compositions. | 2022-06-23 |
20220193123 | LHRH-PLATINUM CONJUGATES FOR TREATING REPRODUCTIVE CANCERS - The conjugation of luteinizing hormone-releasing hormone (LHRH) with activated cisplatin using a malonate linker gives rise to a new Platinum-LHRH conjugate that effectively targets tumor cells that express the LHRH receptor. The Pt-LHRH conjugate may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors. | 2022-06-23 |
20220193124 | Therapeutic Agent for Flavivirus Infection - Provided are an agent for preventing and/or treating a flavivirus infectious disease and a method for preventing and/or treating a flavivirus infectious disease. At least one selected from 5-aminolevulinic acid (5-ALA), a 5-ALA ester, a salt of 5-ALA, or a salt of the 5-ALA ester is used in the agent for preventing and/or treating the flavivirus infectious disease. Examples of the flavivirus to be prevented or treated by 5-ALA or the like can include dengue virus, Zika virus, Japanese encephalitis virus, tick-borne encephalitis virus, West Nile virus, and yellow fever virus. | 2022-06-23 |
20220193125 | MANGANESE COMPOSITION FOR ENHANCING IMMUNITY - An immune enhancement composition and a vaccine composition comprising newly precipitated manganese and/or colloid manganese, a preparation method therefor, and use thereof for immunization and/or vaccination enhancement. | 2022-06-23 |
20220193126 | METHODS OF TREATING IMBALANCE OF PLASMA LIPIDS LEVEL AND FATTY LIVER WITH M2C MACROPHAGES - The present invention discloses methods of treating imbalance of plasma lipids level, fatty liver, nephritis or vascular fibrosis with M2C macrophages. The M2C macrophages used in said methods is prepared by isolating mononuclear cells from bone marrow or peripheral blood, then inducing the mononuclear cells to differentiate into M2 macrophages by macrophage colony stimulating factor (M-CSF), and then inducing the M2 macrophages to polarize into MERTK-expressing M2C macrophages by baicalin. The treatment of imbalance of plasma lipids level comprises increasing proportion of high-density lipoprotein cholesterol in plasma lipids. The invention also provides methods of treating fatty liver and nephritis in a subject in need, comprising the step of administering a therapeutically effective amount of MERTK-expressing M2C macrophages. | 2022-06-23 |
20220193128 | A COMPOSITION, A KIT AND USE THEREOF - The current invention relates to a composition for parenteral administration comprising a mammalian plasma and hyaluronic acid or a salt or ester thereof, wherein said plasma comprises lipids and/or phospholipids. The inventions also relates to a kit comprising one or more aliquots of a composition, said composition comprising a mammalian plasma comprising lipids and/or phospholipids and hyaluronic acid or a derivative thereof and optionally one or more pharmaceutical active ingredients, wherein said kit further comprises one or more aliquots of a calcium source, preferably a calcium chloride solution. The invention also pertains to the composition and kit of current invention for use in the treatment of musculoskeletal diseases. | 2022-06-23 |
20220193129 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF - The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of a therapeutic agent. | 2022-06-23 |
20220193130 | SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOF - The invention relates to DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells. | 2022-06-23 |
20220193131 | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Methods of expanding TILs expressing orthogonal cytokine receptors are provided. Such TILs find use in therapeutic treatment regimens. | 2022-06-23 |
20220193132 | ANTI-EGFRVIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF - Antigen-binding agents such as antibodies or antigen-binding fragments thereof, chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTEs) and the like that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRvIII-specific antibodies or antigen-binding fragments, CARs and BiTEs thereof may be used for the treatment of cancer. Antibody drug conjugates targeting EGFRvIII-expressing cells are particularly contemplated. | 2022-06-23 |
20220193133 | CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY - The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided. | 2022-06-23 |
20220193134 | CO-USE OF LENALIDOMIDE WITH CAR-T CELLS - A method for producing T cells expressing a chimeric antigen receptor (CAR-T cells), comprising: (i) culturing CAR-T cells in a medium comprising lenalidomide or a derivative thereof to produce CAR-T cells, and optionally (ii) administering the CAR-T cells to a subject in need of the treatment. | 2022-06-23 |
20220193135 | MODIFIED IMMUNE EFFECTOR CELL AND PREPARATION METHOD THEREFOR - Provided is a modified immune effector cell, wherein compared with the expression and/or activity of the corresponding gene in a corresponding unmodified cell, the expression and/or activity of the TRAC gene and the HLA-A gene are down-regulated, the expression and/or activity of the B2M gene is not down-regulated, and the expression and/or activity of the CIITA gene is not down-regulated. Also provided is a method for preparing the modified immune effector cell. | 2022-06-23 |
20220193136 | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20 - A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR. | 2022-06-23 |
20220193137 | MODIFIED IMMUNE RECEPTOR CONSTRUCTS - The current disclosure provides for immune cells expressing immune receptors comprising i) a polypeptide having an antigen binding domain, a TCR α-chain constant domain, and a TCR δ-chain transmembrane domain; and/or ii) a polypeptide having an antigen binding domain, a TCR β-chain constant domain, and a TCR γ-chain transmembrane domain. The current disclosure also provides for immune cell expressing immune receptors comprising an antigen binding domain, and a transmembrane domain, wherein the antigen binding domain specifically binds a binding moiety that in turn specifically binds a target, for example, a cancer cell. The immune cells, optionally in combination with the binding moiety, can be used in medical treatment, preferably the treatment of a cancer. | 2022-06-23 |
20220193138 | ENGINEERED NATURAL KILLER CELLS REDIRECTED TOWARD PURINERGIC SIGNALING, CONSTRUCTS THEREOF, AND METHODS FOR USING THE SAME - Polynucleotide constructs and engineered natural killer (NK) cells expressing such constructs are provided for the treatment of cancer and other adenosine-overexpressing disease states. The constructs are a fusion of at least an antigen binding domain specific to an adenosine producing (or adenosine-intermediary producing) cell surface protein and a receptor for promoting cytotoxic or cytolytic activity of the NK cell upon activation, where activation occurs upon the antigen binding domain binding its target cell. Pharmaceutical compositions of the engineered NK cells are also provided, as well as methods of treating an adenosine overexpressing cancer using such pharmaceutical compositions. | 2022-06-23 |
20220193139 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY - Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct. | 2022-06-23 |
20220193140 | WASHED PLATELET EXTRACT - A washed platelet extract with increased platelet growth factor concentration and decreased total protein relative to platelet rich plasma, and methods of making and using such an extract for the treatment of disease and injuries recited herein, are provided. | 2022-06-23 |
20220193141 | COMPOSITIONS COMPRISING STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS AND USES THEREOF TO TREAT NEUROLOGICAL DISEASE - The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing SOX-1 and SOX-2 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing SOX-1 and SOX-2. | 2022-06-23 |
20220193142 | METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF HEMOGLOBINOPATHY - The present invention relates to a method for treating hemoglobinopathy in an individual, comprising: (a) an evaluation step: the evaluation step comprises evaluating the ability of a first population of modified CD34-positive hematopoietic stem cells/progenitor cells to produce a desired level of γ-globin or fetal hemoglobin after differentiation, the modified CD34-positive HSPCs of the first population being derived from the individual and being modified to reduce BCL11A function; and (b) a treatment step: the treatment step comprises administering to the individual a second population of modified CD34-positive HSPCs, the modified CD34-positive HSPCs being derived from the individual and being modified to reduce BCL11A function. At the same time, the invention also relates to a method for treating hemoglobinopathy in individuals, a method for selecting individuals suffering from hemoglobinopathy for treatment using the modified CD34-positive HSPCs of the second population, and a method for determining whether an individual suffering from hemoglobinopathy is suitable or unsuitable for treatment using the second population of modified CD34-positive HSPCs derived from the individual and modified to reduce the function of BCL11A. | 2022-06-23 |
20220193143 | CARTILAGE TISSUE - The invention relates to a method for producing cartilage from pluripotent stem cells (PSCs), the method comprising providing chondrocytes by: 1) providing pluripotent stem cells (PSCs); 2) inducing differentiation of the PSCs into a primitive streak/mesendoderm by culturing the PSCs in hypoxic conditions, in a (mesendodermic) culture media comprising: i) a Wingless/Integrated (WNT) family member, ii) an Activin family member, and iii) a Fibroblast Growth Factor (FGF) family member; 3) inducing differentiation of the primitive streak/mesendoderm into a mesoderm by culturing the primitive streak/mesendoderm in hypoxic conditions, in a (mesodermic) culture media comprising: i) a FGF family member, ii) a bone morphogenetic protein (BMP) family member, iii) Follistatin, and iv) a Neurotrophin (NT); and 4) inducing differentiation of the mesoderm into chondrocytes by culturing the mesoderm in hypoxic conditions, in a (chondroinductive) culture media comprising: i) a FGF family member, ii) a BMP family member, iii) a Neurotrophin, and iv) a Growth/Differentiation Factor (GDF) family member; and forming a pellet of the chondrocytes and culturing the pellet of the chondrocytes in a culture media under hypoxic conditions to produce the cartilage. The invention further relates to methods of chondrocyte production, synthetically produced cartilage, and use in therapy. | 2022-06-23 |
20220193144 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESIS - Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke. | 2022-06-23 |
20220193145 | PROCESS FOR OBTAINING BIOLOGICALLY ACTIVE COMPOSITIONS FROM EMU OIL, ANTIINFLAMMATORY AND ANTI-IRRITANT PHARMACEUTICAL COMPOSITION, AND SKIN REGENERATIVE PHARMACEUTICAL COMPOSITION - A process for obtaining biologically active compositions from emu oil is provided, wherein the compositions are obtained by molecular distillation of the oil, both the distillate and the distillation residue being biologically active compositions. More specifically, a process for obtaining biologically active compositions from refined emu oil is disclosed, which has the following steps: (a) feeding emu oil at a flow of between 1 to 300 kg/h*m2 to a molecular distillation column at a pressure between 0.0001 mbar and 0.05 mbar and at an evaporator temperature between 160° C. and 250° C., for generating a distillate and a residue; and (b) collecting the distillate from the column, the distillate being a biologically active composition, and (c) collecting the residue from the column, the residue being a biologically active composition. | 2022-06-23 |
20220193146 | Composition For Inhibiting Non-Fluorescent Advanced Glycation End Products, And Use Thereof - The present invention relates to a composition for inhibiting non-fluorescent advanced glycation end products, and a use thereof. More specifically, the present invention relates to: a composition for inhibiting non-fluorescent advanced glycation end products, comprising one or more strains selected from the group consisting of | 2022-06-23 |
20220193147 | Anti-aging Composition Containing Akkermansia Muciniphila as Active Ingredient and a Method for Preventing Aging Using Thereof - The present invention relates to a composition containing as an active ingredient at least one selected from the group consisting of | 2022-06-23 |
20220193148 | USE OF NOCARDIA RUBRA CELL WALL SKELETON IN TREATMENT OF THERMAL INJURY - Provided is the use of a | 2022-06-23 |
20220193149 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED EXTRACELLULAR MATRIX COMPONENTS TO IMPROVE DRUG DELIVERY - Provided herein are compositions and methods to treat tumors that include attenuated facultative anaerobic bacterium. The bacterium includes a nucleic acid molecule encoding a recombinant extracellular matrix degrading enzyme operably linked to a promoter. | 2022-06-23 |
20220193150 | Method and System for Reducing the Likelihood of Developing Depression in an Individual - A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising | 2022-06-23 |
20220193151 | THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND/OR PREVENTION OF DYSBIOSIS - Disclosed are methods and compositions for the prevention and treatment of dysbiosis and associated conditions. In particular, described herein are microbial consortia, including monotherapies or minimal microbial consortia, that can prevent and/or cure dysbiosis and associated conditions. In certain embodiments, the therapy comprises | 2022-06-23 |
20220193152 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES - Compositions and methods for converting at least one glucosinolate to an isothiocyanate using | 2022-06-23 |
20220193153 | STRAINS OF LACTOBACILLUS DELBRUECKII WHICH INHIBIT PORPHYROMONAS GINGIVALIS - Disclosed herein are compositions and methods for treating periodontal disease. | 2022-06-23 |
20220193154 | PREOPERATIVE COMPOSITIONS AND METHODS OF PREPARATION THEREOF - Disclosed are preoperative compositions and methods of preparation thereof. The preoperative compositions may be for minimizing thirst, vomiting, insulin resistance, and the like prior to surgery. Such preoperative compositions may also reduce postoperative complications and the need for pain relievers, as well as minimize blood transfusion needed during and after surgery when administered the night before the operation and/or an hour before the operation. The preoperative compositions may include soy milk, isolate milk protein, isolate pea proteins, probiotics, whole milk powder, and micronutrients for example. | 2022-06-23 |
20220193155 | MICROBIAL COMPOSITIONS AND METHODS FOR GREATER TOLERABILITY AND PROLONGED SHELF LIFE - Provided herein are methods and compositions comprising microbial populations with increased tolerability and improved shelf life. Disclosed, herein, in some aspects, is a composition comprising at least one powdered microbial population, lactate, and trehalose. In some embodiments, the lactate is a lactate salt. In some embodiments, the lactate is sodium lactate. In some embodiments, the lactate and trehalose are present in sufficient amount to act as a cryoprotectant. | 2022-06-23 |
20220193156 | PREOPERATIVE COMPOSITIONS AND METHODS OF PREPARATION THEREOF - Disclosed are preoperative compositions and methods of preparation thereof. The preoperative compositions may be for minimizing thirst, vomiting, insulin resistance, and the like prior to surgery. Such preoperative compositions may also reduce postoperative complications and the need for pain relievers, as well as minimize blood transfusion needed during and after surgery when administered the night before the operation and/or an hour before the operation. The preoperative compositions may include soymilk, isolate milk protein, isolate pea proteins, probiotics, whole milk powder, and micronutrients for example. | 2022-06-23 |
20220193157 | LACTOBACILLUS COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MICROBIAL INFECTION - The present invention relates to microbial compositions containing | 2022-06-23 |
20220193158 | COMPOSITION FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER - This invention relates to a composition for use in the treatment of major depressive disorder. In addition, this invention relates to a composition for use in the treatment and/or improvement of mood disturbances and for use in the treatment and/or improvement of the mood state. | 2022-06-23 |
20220193159 | COMPOSITION, PRODUCTION METHOD FOR PRODUCING THE SAME, AND METHOD OF PREVENTING CAKING - The invention provides a composition which contains a bacterial powder and a fatty oil and in which caking of the bacterial powder is suppressed, a method for producing the same, and a method of preventing caking. Provided are a composition including a bacterial powder, a fatty oil, and at least one selected from the group consisting of a microscopic powder and a surfactant, wherein the bacterial powder comprises at least one selected from the group consisting of live cells of lactic acid bacteria, killed cells of lactic acid bacteria, live cells of bifidobacteria, and killed cells of bifidobacteria, a method for producing the same, and a method of preventing caking in a composition containing a fatty oil. | 2022-06-23 |
20220193160 | USE OF SPECIFIC PHAGES FOR THE TREATMENT OF NONTUBERCULOSIS MYCOBACTERIA (NTM) INFECTIONS - Disclosed herein are compositions comprising bacteriophages and methods of using these compositions for treating NTM infections. The present disclosure also provides compositions for screening bacteriophages that are effective in treating NTM infections and methods of using the same. | 2022-06-23 |
20220193161 | LYOPHILIZED VIRUS FORMULATIONS - Provided herein is a powder comprising a live, attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, a sugar alcohol, a source of phosphate, a source of chloride, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids. In exemplary aspects, the powder is a lyophilizate of a liquid composition. Related liquid compositions, methods of preparing an oncolytic virus for administration and methods of treating melanoma are also provided herein. | 2022-06-23 |
20220193162 | FUNGAL EXTRACTS AND FLAVOR COMBINATIONS THEREOF - Disclosed is a composition comprising a combination of at least one flavor compound and a taste-modulating portion of a filamentous fungus mycelial aqueous culture, e.g. a mycelia is from a | 2022-06-23 |
20220193163 | COMPOSITION COMPRISING ACTINIDIA POLYGAMA EXTRACT FOR ALLEVIATING SKIN DAMAGE OR MOISTURIZING SKIN - The present disclosure relates to a composition for alleviating ultraviolet ray-induced skin damage or moisturizing skin, more particularly, to a composition containing an | 2022-06-23 |
20220193164 | EXTRACTION AND PURIFICATION OF CANNABINOIDS - An improved method for making cannabinoids from plant material utilizes the following steps. Plant material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble plant material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the decarboxylated cannabinoids are crystallized/precipitated from the clarified alkaline extract at a pH greater than 7. | 2022-06-23 |
20220193165 | Oral Cannabis Substance and Method of Making Such Substance - Embodiments provide an orally administered substance that contains | 2022-06-23 |
20220193166 | OKRA AS A SUBSTITUTE FOR CERVICAL MUCUS - Artificial cervical fluid is disclosed that contains a mucilaginous extract from the okra plant. The mucilaginous extract can be produced using a hot aqueous extractant or cold extraction process followed by separation of larger particles from the extract. The extract finds many uses, for example as a sperm storage medium, a sperm freezing medium, a sexual lubricant, an artificial insemination medium, and an in vitro fertilization medium. | 2022-06-23 |
20220193167 | COMBINATION THERAPY FOR TREATMENT OF SKIN DISEASES - Described herein are pharmaceutical compositions comprising one or more modulators of a cytochrome 450 enzyme (CYP450) and substituted or unsubstituted diindolylmethane. Also described herein are methods for treating one or more skin conditions by administering a combination therapy comprising substituted or unsubstituted diindolylmethane and one or more modulators of CYP450. In particular, methods are disclosed for improving bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following the combination therapy. | 2022-06-23 |
20220193168 | HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF RHODIOLA PLANTS - A method of extracting a | 2022-06-23 |
20220193169 | ANTI-INFLAMMATORY COMPOSITION - A composition having a non-polar fraction obtained from at least one fermented plant material is provided. The at least one plant material has been subjected to a lactic acid fermentation. | 2022-06-23 |
20220193170 | Nutraceutical Reduction Prevention and/or Reversion of Multiple Sclerosis - Disclosed are compositions of matter, protocols, and treatment means for preventing and/or reversing multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or | 2022-06-23 |
20220193171 | PHARMACEUTICAL COMPOSITION COMPRISING MIXTURE EXTRACT OF COPTIS RHIZOME AND SCHIZONEPETA TENUIFOLIA AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to a pharmaceutical composition comprising a mixture extract of Coptis Rhizome and | 2022-06-23 |
20220193172 | COMPOSITION FOR USE IN IMPROVING ENDOTHELIAL FUNCTION BY ENHANCING FLOW MEDIATED DILATION - The present invention relates to a composition comprising esterase treated decaffeinated green coffee extract (HDGCE) for use in a method of improving cardiovascular endpoints such as endothelial function by enhancing flow mediated dilation in a subject, wherein the subject is administered an effective dose of HDGCE with an amount of 100-400 mg/day. | 2022-06-23 |
20220193173 | Traditional Chinese Medicine Composition for Loosening Bowel to Relieve Constipation, Preparation Method and Application Thereof - The present disclosure discloses a traditional Chinese medicine composition for loosening bowel to relieve constipation as well as a preparation method and an application thereof. The traditional Chinese medicine composition is prepared by extracting aloe and fructus aurantii with a mass ratio of 2-5:1-10. | 2022-06-23 |
20220193174 | NASAL SPRAY FOR PREVENTING INFLUENZA BASED ON RED PEPPER EXTRACT AND HEPARIN AND PREPARATION METHOD THEREOF - The present disclosure belongs to the technical field of medicine preparation, and particularly relates to a nasal spray for preventing influenza based on a red pepper extract and heparin and a preparation method thereof. A nasal spray consists of the following raw materials in parts by weight: 10% γ-PGA-CS, 5-10% glycerol, 2% red pepper extract, 5-10% heparin solution, 2-2.4% ethanol and balance of purified water. The present disclosure can not only inhibit germs and diminish inflammation, and has a better therapeutic effect on rhinitis, but also can keep the inner surface of a nasal cavity moist for a long time. Moreover, the present disclosure can reduce side effects on a human body by changing the type of bactericides in the nasal spray, thus keeping the nasal cavity clean and moist for a long time. | 2022-06-23 |
20220193175 | FUNCTIONAL TEA CONTAINING BENEFICIAL INGREDIENTS FOR THE HUMAN BODY - The present disclosure relates to a functional tea containing beneficial ingredients for the human body. | 2022-06-23 |